A phase II study of BAY 43–9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC)

Authors

Siu LL; Winquist E; Agulnik M; Chin SF; Pond GR; Cheiken R; Francis P; Petrenciuc O; Chen E

Journal of Clinical Oncology, Vol. 23, No. 16_suppl, pp. 5566–5566

American Society of Clinical Oncology (ASCO)

6 2005

10.1200/jco.2005.23.16_suppl.5566

0732-183X

Gregory Pond